SYRS
Price
$0.22
Change
+$0.02 (+10.00%)
Updated
Jan 17 closing price
Capitalization
5.89M
46 days until earnings call
VKTX
Price
$32.65
Change
+$0.09 (+0.28%)
Updated
Jan 17 closing price
Capitalization
3.64B
17 days until earnings call
Ad is loading...

SYRS vs VKTX

Header iconSYRS vs VKTX Comparison
Open Charts SYRS vs VKTXBanner chart's image
Syros Pharmaceuticals
Price$0.22
Change+$0.02 (+10.00%)
Volume$1.18M
Capitalization5.89M
Viking Therapeutics
Price$32.65
Change+$0.09 (+0.28%)
Volume$4.39M
Capitalization3.64B
SYRS vs VKTX Comparison Chart
Loading...
SYRS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
VKTX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
SYRS vs. VKTX commentary
Jan 19, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is SYRS is a Hold and VKTX is a Hold.

Ad is loading...
COMPARISON
Comparison
Jan 19, 2025
Stock price -- (SYRS: $0.22 vs. VKTX: $32.65)
Brand notoriety: SYRS and VKTX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: SYRS: 9% vs. VKTX: 117%
Market capitalization -- SYRS: $5.89M vs. VKTX: $3.64B
SYRS [@Biotechnology] is valued at $5.89M. VKTX’s [@Biotechnology] market capitalization is $3.64B. The market cap for tickers in the [@Biotechnology] industry ranges from $368.92B to $0. The average market capitalization across the [@Biotechnology] industry is $2.37B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

SYRS’s FA Score shows that 1 FA rating(s) are green whileVKTX’s FA Score has 0 green FA rating(s).

  • SYRS’s FA Score: 1 green, 4 red.
  • VKTX’s FA Score: 0 green, 5 red.
According to our system of comparison, VKTX is a better buy in the long-term than SYRS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

SYRS’s TA Score shows that 4 TA indicator(s) are bullish while VKTX’s TA Score has 4 bullish TA indicator(s).

  • SYRS’s TA Score: 4 bullish, 2 bearish.
  • VKTX’s TA Score: 4 bullish, 3 bearish.
According to our system of comparison, SYRS is a better buy in the short-term than VKTX.

Price Growth

SYRS (@Biotechnology) experienced а -2.49% price change this week, while VKTX (@Biotechnology) price change was -16.94% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.44%. For the same industry, the average monthly price growth was +2.66%, and the average quarterly price growth was -1.92%.

Reported Earning Dates

SYRS is expected to report earnings on May 01, 2025.

VKTX is expected to report earnings on Apr 23, 2025.

Industries' Descriptions

@Biotechnology (-1.44% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
VKTX($3.64B) has a higher market cap than SYRS($5.89M). SYRS YTD gains are higher at: -4.526 vs. VKTX (-18.862). SYRS has higher annual earnings (EBITDA): -91.14M vs. VKTX (-133.66M). VKTX has more cash in the bank: 930M vs. SYRS (58.3M). VKTX has less debt than SYRS: VKTX (1.24M) vs SYRS (60.2M). SYRS has higher revenues than VKTX: SYRS (386K) vs VKTX (0).
SYRSVKTXSYRS / VKTX
Capitalization5.89M3.64B0%
EBITDA-91.14M-133.66M68%
Gain YTD-4.526-18.86224%
P/E RatioN/AN/A-
Revenue386K0-
Total Cash58.3M930M6%
Total Debt60.2M1.24M4,874%
FUNDAMENTALS RATINGS
SYRS vs VKTX: Fundamental Ratings
SYRS
VKTX
OUTLOOK RATING
1..100
3272
VALUATION
overvalued / fair valued / undervalued
1..100
73
Overvalued
48
Fair valued
PROFIT vs RISK RATING
1..100
10060
SMR RATING
1..100
10092
PRICE GROWTH RATING
1..100
6664
P/E GROWTH RATING
1..100
8100
SEASONALITY SCORE
1..100
n/a75

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

VKTX's Valuation (48) in the Biotechnology industry is in the same range as SYRS (73). This means that VKTX’s stock grew similarly to SYRS’s over the last 12 months.

VKTX's Profit vs Risk Rating (60) in the Biotechnology industry is somewhat better than the same rating for SYRS (100). This means that VKTX’s stock grew somewhat faster than SYRS’s over the last 12 months.

VKTX's SMR Rating (92) in the Biotechnology industry is in the same range as SYRS (100). This means that VKTX’s stock grew similarly to SYRS’s over the last 12 months.

VKTX's Price Growth Rating (64) in the Biotechnology industry is in the same range as SYRS (66). This means that VKTX’s stock grew similarly to SYRS’s over the last 12 months.

SYRS's P/E Growth Rating (8) in the Biotechnology industry is significantly better than the same rating for VKTX (100). This means that SYRS’s stock grew significantly faster than VKTX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
SYRSVKTX
RSI
ODDS (%)
Bullish Trend 12 days ago
79%
Bullish Trend 12 days ago
76%
Stochastic
ODDS (%)
Bullish Trend 12 days ago
84%
Bullish Trend 12 days ago
83%
Momentum
ODDS (%)
Bullish Trend 12 days ago
82%
Bearish Trend 12 days ago
90%
MACD
ODDS (%)
N/A
Bullish Trend 12 days ago
89%
TrendWeek
ODDS (%)
Bearish Trend 12 days ago
90%
Bullish Trend 12 days ago
83%
TrendMonth
ODDS (%)
Bearish Trend 12 days ago
90%
Bearish Trend 12 days ago
85%
Advances
ODDS (%)
Bullish Trend 14 days ago
78%
Bullish Trend 17 days ago
83%
Declines
ODDS (%)
Bearish Trend 12 days ago
90%
Bearish Trend 12 days ago
84%
BollingerBands
ODDS (%)
Bearish Trend 12 days ago
90%
N/A
Aroon
ODDS (%)
N/A
Bearish Trend 12 days ago
85%
View a ticker or compare two or three
Ad is loading...
SYRS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
VKTX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
GSUSX51.860.48
+0.93%
Goldman Sachs US Equity Insights C
AMFEX18.390.16
+0.88%
AAMA Equity
WSHCX61.780.48
+0.78%
American Funds Washington Mutual C
TIVFX15.590.04
+0.26%
American Beacon EAM Int Small Cap Cl
AAAVX11.780.03
+0.26%
DWS RREEF Real Assets R6

SYRS and

Correlation & Price change

A.I.dvisor indicates that over the last year, SYRS has been loosely correlated with XFOR. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if SYRS jumps, then XFOR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SYRS
1D Price
Change %
SYRS100%
+7.02%
XFOR - SYRS
48%
Loosely correlated
+10.06%
ORMP - SYRS
33%
Poorly correlated
-1.72%
KNTPF - SYRS
32%
Poorly correlated
N/A
AXON - SYRS
30%
Poorly correlated
+1.37%
VKTX - SYRS
30%
Poorly correlated
+0.28%
More

VKTX and

Correlation & Price change

A.I.dvisor indicates that over the last year, VKTX has been loosely correlated with JANX. These tickers have moved in lockstep 61% of the time. This A.I.-generated data suggests there is some statistical probability that if VKTX jumps, then JANX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To VKTX
1D Price
Change %
VKTX100%
+0.28%
JANX - VKTX
61%
Loosely correlated
+0.27%
DNLI - VKTX
49%
Loosely correlated
+1.20%
LGND - VKTX
44%
Loosely correlated
+0.73%
BEAM - VKTX
41%
Loosely correlated
+0.17%
ALT - VKTX
40%
Loosely correlated
+2.24%
More